This is the authors' abstract. We don't add key points for this paper.
Hidradenitis suppurativa (HS) is a painful inflammatory disorder of follicular biology. Androgens are believed to play a role in HS pathogenesis; however, the mechanism remains unclear. The high frequency of polycystic ovary disease (PCOS) in HS suggests the influence of testosterone as a driver of disease. In order to assess the impact of PCOS on HS severity, we conducted a retrospective chart review of 55 female patients with HS-PCOS and 57 female HS-controls. Demographic information and disease severity (as measured by HS-physician global assessment, numerical rating scale-pain score, erythrocyte sedimentation rate, c-reactive protein, interleukin-6, testosterone levels, hemoglobin A1C, and treatment protocols) were recorded. Testosterone levels in the HS-PCOS cohort were statistically higher than controls ( p < 0.05). Binomial logistic regressions showed no statistical differences in age, sex, race, HS severity, and inflammatory markers when comparing the HS-PCOS cohort with HS-controls. Additionally, there were no significant differences in the range and frequency of HS therapies in these groups. Study limitations include small sample size and cross-sectional design. We report that patients with HS-PCOS have neither increased HS disease severity nor require more aggressive treatments than HS-controls.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Romanelli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: